Moss-produced, glycosylation-optimized human factor H for therapeutic application in complement disorders
Michelfelder S, Parsons J, Bohlender LL, Hoernstein SN, Niederkrüger H, Busch A, Krieghoff N, Koch J, Fode B, Schaaf A, Frischmuth T, Pohl M, Zipfel PF, Reski R, Decker EL, Häffner K.
J Am Soc Nephrol. 2017;28(5):1462-147
J Am Soc Nephrol. online article
Mutations in the complement-regulatory glycoprotein factor H can lead to severe renal and eye disease, however, no therapeutical factor H is commercially available yet. Here, we present the production of a glyco-optimized recombinant factor H in Physcomitrella patens which showed full bioactivity similar to plasma-derived factor H. The therapeutic potential of moss-derived factor H was proven in a murine model of C3 glomerulopathy in vivo.
